MX378261B - Formas de dosificación sólidas de liberación prolongada antieméticas. - Google Patents

Formas de dosificación sólidas de liberación prolongada antieméticas.

Info

Publication number
MX378261B
MX378261B MX2015012970A MX2015012970A MX378261B MX 378261 B MX378261 B MX 378261B MX 2015012970 A MX2015012970 A MX 2015012970A MX 2015012970 A MX2015012970 A MX 2015012970A MX 378261 B MX378261 B MX 378261B
Authority
MX
Mexico
Prior art keywords
amount
antiemetic
drug
dosage forms
solid dosage
Prior art date
Application number
MX2015012970A
Other languages
English (en)
Spanish (es)
Other versions
MX2015012970A (es
Inventor
Gilead Raday
Reza Fathi
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX378261(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of MX2015012970A publication Critical patent/MX2015012970A/es
Publication of MX378261B publication Critical patent/MX378261B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015012970A 2013-03-14 2014-03-14 Formas de dosificación sólidas de liberación prolongada antieméticas. MX378261B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782395P 2013-03-14 2013-03-14
PCT/IB2014/001633 WO2014181195A2 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms

Publications (2)

Publication Number Publication Date
MX2015012970A MX2015012970A (es) 2016-04-11
MX378261B true MX378261B (es) 2025-03-10

Family

ID=51528070

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012970A MX378261B (es) 2013-03-14 2014-03-14 Formas de dosificación sólidas de liberación prolongada antieméticas.

Country Status (19)

Country Link
US (5) US9636305B2 (OSRAM)
EP (1) EP2983664B1 (OSRAM)
JP (1) JP6282676B2 (OSRAM)
KR (1) KR102270521B1 (OSRAM)
CN (2) CN112274489A (OSRAM)
AU (1) AU2014264342B2 (OSRAM)
BR (1) BR112015022398B1 (OSRAM)
CA (1) CA2905553C (OSRAM)
CL (1) CL2015002666A1 (OSRAM)
ES (1) ES2946985T3 (OSRAM)
HK (1) HK1223012A1 (OSRAM)
IL (1) IL241580B (OSRAM)
MX (1) MX378261B (OSRAM)
NZ (1) NZ712159A (OSRAM)
PH (1) PH12015502093B1 (OSRAM)
RU (1) RU2679448C2 (OSRAM)
SG (1) SG11201507450TA (OSRAM)
WO (2) WO2014184662A2 (OSRAM)
ZA (1) ZA201506961B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102270521B1 (ko) 2013-03-14 2021-06-30 레드힐 바이오파마 엘티디 구토억제 서방형 고체 제형
CA2941829C (en) * 2014-03-11 2021-11-02 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2020080875A1 (ko) * 2018-10-19 2020-04-23 주식회사 삼양바이오팜 아프레피탄트의 경구용 조성물
US11969416B1 (en) 2022-11-03 2024-04-30 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE60019334T2 (de) * 1999-12-09 2005-09-08 Alza Corp., Mountain View Antivirale arznei
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) * 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
US20050131045A1 (en) 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
PL378369A1 (pl) 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
PL1683526T3 (pl) 2003-11-14 2012-09-28 Senju Pharma Co Preparat wodnego roztworu zawierający antybiotyk aminoglikozydowy i bromfenak
AU2005237360B2 (en) * 2004-04-30 2010-10-21 Astellas Pharma Inc. Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
BRPI0621996B8 (pt) * 2006-08-18 2022-07-05 Evonik Roehm Gmbh preparação farmacêutica compreendendo um núcleo com um ingrediente ativo e com um ácido orgânico e/ou com o sal de um ácido orgânico, e um revestimento que envolve o núcleo e que compreende um ou mais copolímeros de (met)acrilato, e seu uso.
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
MX2009004439A (es) * 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
JP2010514679A (ja) * 2006-12-22 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー 制御放出組成物及び方法
WO2009118763A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20100196291A1 (en) * 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
EP2403487A2 (en) * 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
RU2427389C2 (ru) * 2009-10-09 2011-08-27 Александр Владимирович Диковский Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
RU2012131158A (ru) * 2009-12-22 2014-01-27 Эбботт Хелткеа Прайвит Лимитед Фармацевтическая композиция с контролируемым высвобождением лекарственного средства
AU2010343147A1 (en) 2009-12-28 2012-07-19 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120128730A1 (en) * 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron
KR102270521B1 (ko) 2013-03-14 2021-06-30 레드힐 바이오파마 엘티디 구토억제 서방형 고체 제형

Also Published As

Publication number Publication date
EP2983664A4 (en) 2017-01-04
CA2905553A1 (en) 2014-11-13
SG11201507450TA (en) 2015-10-29
WO2014184662A2 (en) 2014-11-20
PH12015502093A1 (en) 2016-01-18
EP2983664A2 (en) 2016-02-17
CN105530935A (zh) 2016-04-27
KR102270521B1 (ko) 2021-06-30
JP6282676B2 (ja) 2018-02-21
RU2679448C2 (ru) 2019-02-11
ZA201506961B (en) 2017-03-29
KR20150127253A (ko) 2015-11-16
HK1223012A1 (zh) 2017-07-21
EP2983664B1 (en) 2023-04-19
US20180028452A1 (en) 2018-02-01
ES2946985T3 (es) 2023-07-31
WO2014181195A2 (en) 2014-11-13
US20140271887A1 (en) 2014-09-18
RU2015143993A (ru) 2017-04-20
IL241580B (en) 2020-08-31
CA2905553C (en) 2021-04-06
US9636305B2 (en) 2017-05-02
US20170189340A1 (en) 2017-07-06
JP2016512493A (ja) 2016-04-28
BR112015022398B1 (pt) 2022-01-11
NZ712159A (en) 2019-12-20
CN112274489A (zh) 2021-01-29
RU2015143993A3 (OSRAM) 2018-03-21
US20200330392A1 (en) 2020-10-22
WO2014184662A3 (en) 2015-04-02
AU2014264342A1 (en) 2015-10-01
PH12015502093B1 (en) 2018-09-26
MX2015012970A (es) 2016-04-11
CL2015002666A1 (es) 2017-02-17
WO2014181195A3 (en) 2015-12-17
US20140271851A1 (en) 2014-09-18
BR112015022398A2 (pt) 2017-07-18
BR112015022398A8 (pt) 2019-11-26
AU2014264342B2 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
PH12014501446A1 (en) Solid nicotine-comprising dosage form with reduced organoleptic disturbance
PH12015501756A1 (en) Tamper resistant pharmaceutical formulations
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
UY31698A (es) Preparacion solida de desintegracion oral
UA117685C2 (uk) Складена композиція для перорального введення, яка містить езетиміб та розувастатин
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
MX2015005534A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX2012013021A (es) Formulaciones resistentes a alcohol.
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
PH12020550806A1 (en) Core tablet composite preparation comprising mosapride and rabeprazole
MX2016005477A (es) Formas de dosificacion disuasivas del abuso.
MD4538B1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX385881B (es) Forma de dosificacion de alivio prolongado
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
PH12016501756B1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
PH12016500693B1 (en) Slow-release solid oral compositions
PE20160520A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
MX2015013470A (es) Microcapsulas de piperaquina y composiciones que las contienen.
BR112014026040A2 (pt) tablete de liberação sustentada que contém levodropropizina e método para preparar o mesmo
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol